Cart
sales@molnova.com
KAN0438757
CAS No. 1451255-59-6
KAN0438757( —— )
Catalog No. M23618 CAS No. 1451255-59-6
KAN0438757 is a selective and potent inhibitor of the metabolic kinase PFKFB3 with an IC50 of 0.19 μM.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 206 | In Stock |
|
| 5MG | 192 | In Stock |
|
| 10MG | 307 | In Stock |
|
| 25MG | 554 | In Stock |
|
| 50MG | 745 | In Stock |
|
| 100MG | 1014 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameKAN0438757
-
NoteResearch use only, not for human use.
-
Brief DescriptionKAN0438757 is a selective and potent inhibitor of the metabolic kinase PFKFB3 with an IC50 of 0.19 μM.
-
DescriptionKAN0438757 is a selective and potent inhibitor of the metabolic kinase PFKFB3 with an IC50 of 0.19 μM.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayCytoskeleton/Cell Adhesion Molecules
-
TargetGlucokinase
-
RecptorPFKFB3
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1451255-59-6
-
Formula Weight447.43
-
Molecular FormulaC21H18FNO7S
-
Purity>98% (HPLC)
-
SolubilityDMSO:130 mg/mL (290.55 mM; Need ultrasonic)
-
SMILESC1=CC(=CC(=C1)S(=O)(=O)NC2=CC(=C(C=C2)C(=O)OCCO)O)C3=C(C=CC(=C3)F)O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Gustafsson NMS, et al. Targeting PFKFB3 radiosensitizes cancer cells and suppresses homologous recombination. Nat Commun. 2018 Sep 24;9(1):3872.
molnova catalog
related products
-
MK-0941 mesylate
MK-0941 mesylate (MK0941) is a novel potent, orally active Glucokinase (GK) activator with EC50 of 0.240 and 0.065 uM in 2.5 and 10 mM glucose, respectively.
-
Fluticasone furoate
Fluticasone furoate is a synthetic trifluorinated corticosteroid derived from fluticasone with a Kd of 0.3 nM.
-
Diosbulbin B
Diosbulbin B has potential anti-tumor effects which may be related to influencing the immune system for the first time.
